Live Breaking News & Updates on கிரேக் ஜான்ஸ்டோன்

Stay updated with breaking news from கிரேக் ஜான்ஸ்டோன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toul


Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse
DGAP-News: Evotec SE
/ Key word(s): Miscellaneous
20.04.2021 / 07:30
J.POD
(R) 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19
EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE
CONSTRUCTION OF THE J.POD
Hamburg, Germany, 20 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD
(R) 2 EU biologics manufacturing facility at Evotec s Campus Curie in Toulouse, France. J.POD ....

France General , United States , Evotec Toulouse , Toulouse Metropole , Werner Lanthaler , Craig Johnstone , Sanofi Evotec , Volker Braun , Carole Delga , Jean Luc Moudenc , Evotec Biologics , Gabriele Hansen , United States Department Of Defense , Boehringer Ingelheim , Melinda Gates Foundation , Evotec Se Frankfurt Stock Exchange , Distribution Services , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Health Campus Of The , Novo Nordisk , Frankfurt Stock Exchange , Campus Curie , United States Department , Occitanie Region , Chief Executive Officer ,

Evotec AG: Evotec And Exscientia Announce Start of Human Clinical Trials of Novel Immuno-Oncology Drug


Evotec AG: Evotec And Exscientia Announce Start of Human Clinical Trials of Novel Immuno-Oncology Drug
EXSCIENTIA TO LEAD CLINICAL DEVELOPMENT PHASE
EVOTEC RETAINS CO-OWNERSHIP RIGHTS DURING CLINICAL DEVELOPMENT
HAMBURG, GERMANY / ACCESSWIRE / April 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia s next generation 3-D evolutionary AI-design platform, Centaur Chemist
(R). The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesir ....

Volker Braun , Andrew Hopkins , Gabriele Hansen , Craig Johnstone , Boehringer Ingelheim , Evotec Se Frankfurt Stock Exchange , Head Of Global Corporate Communications Marketing , Bristol Myers Squibb , Novo Nordisk , Frankfurt Stock Exchange , Chief Operating Officer , Artificial Intelligence , Global Corporate Communications , Global Investor Relations , வோல்கர் மூளை , ஆண்ட்ரூ ஹாப்கின்ஸ் , கேப்ரியல் ஹேன்சன் , கிரேக் ஜான்ஸ்டோன் , போஹெரிங்கர் இஂகல்‌ஹைம் , தலை ஆஃப் உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் சந்தைப்படுத்தல் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , பிராங்க்ஃபர்ட் ஸ்டாக் பரிமாற்றம் , தலைமை இயங்குகிறது அதிகாரி , செயற்கை உளவுத்துறை , உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் , உலகளாவிய முதலீட்டாளர் உறவுகள் ,